Navigation Links
Omeros Announces Submission to European Medicines Agency of Paediatric Investigation Plan Letter of Intent for OMS302
Date:11/29/2011

SEATTLE, Nov. 29, 2011 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has submitted to the European Medicines Agency (EMA) a letter of intent to file its Paediatric Investigation Plan (PIP) for OMS302, the Company's product candidate for use during intra-ocular lens replacement surgery. A PIP is part of the EMA approval process and must be agreed prior to submission of a Marketing Authorization Application (MAA) for the drug in the European Union, unless the requirement is waived. A PIP describes how a company intends to evaluate the use of a given drug in children. Completion of studies outlined in the PIP prior to EU approval is not a requirement for MAA submission.

OMS302 is being evaluated in a Phase 3 clinical program enrolling both cataract surgery and refractive lens exchange patients.  The drug is added to standard irrigation solution used during cataract and other lens replacement surgery to maintain intraoperative mydriasis (pupil dilation) and reduce postoperative pain. Two randomized, double-blind, placebo-controlled, multicenter trials are planned. The first trial is underway in North America, and data are expected in the first quarter of 2012.  Omeros plans to initiate the second trial following discussions with regulators to ensure that data collected meet European expectations for marketing approval. The co-primary endpoints for these trials – maintenance of intraoperative pupil dilation (mydriasis) and reduction of postoperative pain – are the same as those achieved in the recently completed 221-patient Phase 2b trial. In that study, OMS302 was significantly superior to vehicle both in reducing postoperative pain and maintaining mydriasis.

"We remain on track to announce data from the initial Phase 3 trial of OMS302 in the first quarter of 2012," said Gregory A. Demopulos, M.D., chairman and chief e
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
2. Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
3. Omeros Announces Patient Enrollment in Phase 1/Phase 2 Study of OMS302
4. Omeros and The Parkinsons Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
5. Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
6. Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
7. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
8. Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
9. Daniel K. Spiegelman Elected to Board of Directors of Omeros
10. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
11. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... SAN DIEGO , Feb. 27, 2015 /PRNewswire/ ... three-dimensional biology company focused on delivering breakthrough 3D ... , President and Chief Executive Officer, will present ... "We invite you to join us for ... to provide updates on our commercial launch of ...
(Date:2/27/2015)... MINNEAPOLIS , Feb. 27, 2015  Uroplasty, Inc. (NASDAQ: ... develops, manufactures and markets innovative proprietary products to treat ... the 27th Annual ROTH Conference on Tuesday, March 10, ... Brett Reynolds , Chief Financial Officer, will present ... one on one at the conference at the Ritz ...
(Date:2/27/2015)... Mass. and JERUSALEM , ... biopharma company developing octreotide capsules, its lead product for ... a $70 million Series E financing round. Participants in ... Sofinnova Ventures, and an undisclosed blue chip public investment ... Capital, 7 Med Health Ventures, Abingworth and ARCH Venture ...
Breaking Medicine Technology:Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 2Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 3Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 4Uroplasty to Participate in the 27th Annual ROTH Conference 2Chiasma Announces Completion of $70 Million Series E Financing 2Chiasma Announces Completion of $70 Million Series E Financing 3
... 2011 - Vention Medical, a leading full-service ... acquisition of ANSAmed, Ireland,s premier  provider of ... and multi-lumen extrusion capabilities, and catheter design, ... acquisition of ANSAmed will expand Vention Medical,s ...
... 26, 2011 Varian Medical Systems (NYSE: VAR ... with Bank of America, N.A. to repurchase $250 million of ... the company amended its revolving credit facility with Bank of ... to $300 million. Under the accelerated repurchase agreement, ...
Cached Medicine Technology:Vention Medical Acquires ANSAmed 2Varian Medical Systems Announces $250 Million Accelerated Stock Repurchase; Increases Its Revolving Credit Facility 2Varian Medical Systems Announces $250 Million Accelerated Stock Repurchase; Increases Its Revolving Credit Facility 3
(Date:3/1/2015)... GA (PRWEB) March 01, 2015 ... Evelyn King and Carolyn Roddy to the professional staff ... of Compliance, graduated from The Ohio State University-Mortiz College ... 15 years of experience working with several Fortune 500 ... in the area of corporate benefits. Her experiences range ...
(Date:3/1/2015)... 2015 Theme and plugin developers from ... pack for Final Cut Pro X entitled Transccordion. ... to any FCPX editors project.” Said Christiana Austin, CEO ... tools needed to easily drag and drop their accordion ... many different controls over the parameters of this transition ...
(Date:2/28/2015)... Malaysia (PRWEB) February 28, 2015 The ... all across Malaysia into one platform and gears towards ... , A series of group talks in smaller ... like Nation Building, Education, Personal Development, Leadership, Entrepreneurship, Healthcare, ... and raise awareness of Malaysian youths. , ...
(Date:2/28/2015)... March 01, 2015 Heart diseases are ... 10 percent of urban adult population and 5 percent ... heart diseases and 20-30 percent of them require specialized ... ailments and coronary vascular diseases (CVD). , A division ... new market research report titled “Indian Coronary Stent Market ...
(Date:2/28/2015)... Gerald “Solutionman” Haman surveyed over 10,000 people ... innovative thinking. “The #1 block was lack of ... reports Haman, who created the Thinkubator Innovation Studio in ... that they did not have enough time for innovative ... stimulate innovation. , Solutionman’s monthly “Accelerating Innovation Training” workshops ...
Breaking Medicine News(10 mins):Health News:ERISAPros Recruits Evelyn King, J.D. and Carolyn Roddy, J.D. to its Professional Staff 2Health News:Announcing a New Transition Pack from Pixel Film Studios, Transccordion for Final Cut Pro X 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 3Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 4Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 2Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 3
... (HealthDay News) -- Patients who receive artificial joints made with ... loosen the new joint, according to a new study of ... Contrary to previous studies that blamed bacteria for the ... New Jersey reported that tiny titanium particles that flake off ...
... can be lulled to sleep by a factor released by ... in the Journal of Experimental Medicine ( www.jem.org ... patients after treatment, often as a result of metastases that ... at Southern Illinois University School of Medicine now show that ...
... may think about sex more often than women do, but a ... such as eating and sleep, more frequently than women do, as ... think about sex every seven seconds, which would amount to more ... study, the median number of young men,s thought about sex stood ...
... ,Heart function improved in obese people with type 2 diabetes ... says. Researchers measured body-mass index (BMI) and used MRI ... people (seven men and eight women) with type 2 diabetes ... diet. Pericardial fat collects around the heart and can ...
... in the developing world getting enough food to eat is ... A new issue of the international journal Energy Policy ... using the only energy source available to many people, woody ... of decision frameworks that are needed to guide policy development ...
... HILL Scientists at the ,University of North Carolina at ... that plays a central role in the formation of new ... and new blood vessel formation, or angiogenesis, is seriously impaired ... 16, 2011 in the journal Blood , was led ...
Cached Medicine News:Health News:Study debunks stereotype that men think about sex all day long 2Health News:Study debunks stereotype that men think about sex all day long 3Health News:Study debunks stereotype that men think about sex all day long 4Health News:Low-Cal Diet Cuts Fat Around Heart in Obese People: Study 2Health News:Saving millions of lives and protecting our climate through clean cooking options 2Health News:Saving millions of lives and protecting our climate through clean cooking options 3Health News:Cell molecule identified as central player in the formation of new blood vessels 2Health News:Cell molecule identified as central player in the formation of new blood vessels 3
... Centuries of German Craftsmanship have ... in the world. Ocutek now ... Only holders of the coveted ... eight-year apprenticeship, are qualified to ...
... of German Craftsmanship have produced ... the world. Ocutek now makes ... holders of the coveted Meisterbrief ... apprenticeship, are qualified to become ...
... Centuries of German Craftsmanship ... instrumentation in the world. Ocutek ... you! Only holders of the ... and eight-year apprenticeship, are qualified ...
... Centuries of German Craftsmanship ... instrumentation in the world. Ocutek ... you! Only holders of the ... and eight-year apprenticeship, are qualified ...
Medicine Products: